EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma

Junyi Li iD, Michael Z Liao iD, Justin Wilkins iD, Elicia Penuel, Bei Wang iD, Shweta Vadhavkar iD, Kun Peng iD, Junning Cao, Zhiming Li iD, Ye Zhang iD, Wenjin Li iD, Donghang Li iD und 7 weitere

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70211 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Junyi Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Neoplasm Recurrence, Local, Antibodies, Bispecific, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mosunetuzumab, a CD20 × CD3 T‐cell‐engaging bispecific antibody, redirects T cells to eliminate malignant B cells. The purpose of YO43555 was to assess the pharmacokinetics (PK), safety, tolerability, and efficacy of mosunetuzumab as a single agent in Chinese patients with relapsed/refractory follicular lymphoma (R/R FL). The impact of ethnicity/region on the PK disposition of mosunetuzumab was assessed by non‐compartmental analysis (NCA) as well as a population PK (popPK) approach. A previously established popPK model for intravenous mosunetuzumab, built from the global Phase I/II study GO29781, was externally validated with the PK data from study YO43555. Results from the PK analysis showed that the global popPK model adequately captured the individual PK of the Chinese population. The model predicted mosunetuzumab exposure metrics in Chinese patients were similar to those observed in Asian patients in the GO29781 R/R FL subpopulation with the same dose regimen, while the exposure differences between Chinese and Non‐Asians from the global population were < 20%. An overlay of the exposure levels for Chinese patients on the established E‐R relationship in global patients indicated that the mosunetuzumab exposure of Chinese patients remained within the established bounds for clinical safety and efficacy. The cytokine biomarkers IL‐6 and TNF‐α showed similar time‐course patterns of release as observed in globally enrolled patients. In summary, mosunetuzumab PK disposition did not show significant ethnic sensitivity that would impact patient outcomes. Therefore, dose adjustment of the globally approved mosunetuzumab regimen is not warranted for Chinese patients with R/R FL. Trial Registration: ClinicalTrials.gov identifier: NCT02500407

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularNeoplasm Recurrence, LocalAntibodies, BispecificAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAdultAgedChinaTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

cytokine biomarkerspopulation PK analysisrace and ethnicity

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Genentech, Inc, South San Francisco, California, USA.
  • Occams, Amstelveen, the Netherlands.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Roche (China) Holding Ltd, Shanghai, China.

ORCID-Profile: Junyi Li, Michael Z Liao, Justin Wilkins, Bei Wang, Shweta Vadhavkar, Kun Peng, Zhiming Li, Ye Zhang, Wenjin Li, Donghang Li, Mingzhu Zhou, Michael C Wei, Rong Zhao, Chunze Li, Chi-Chung Li, David C Turner

Zitieren

APA

Li, J., Liao, M. Z., Wilkins, J., Penuel, E., Wang, B., Vadhavkar, S., Peng, K., Cao, J., Li, Z., Zhang, Y., Li, W., Li, D., Zhou, M., Wei, M. C., Kwan, A., Zhao, R., Li, C., Li, C. C., & Turner, D. C. (2025). Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma. Clinical and Translational Science. https://doi.org/10.1111/cts.70211

Vancouver

Li J, Liao MZ, Wilkins J, Penuel E, Wang B, Vadhavkar S, et al. Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma. Clinical and Translational Science. 2025. doi:10.1111/cts.70211

BibTeX
@article{Li2025,
  author = {Li, Junyi and Liao, Michael Z and Wilkins, Justin and Penuel, Elicia and Wang, Bei and Vadhavkar, Shweta and Peng, Kun and Cao, Junning and Li, Zhiming and Zhang, Ye and Li, Wenjin and Li, Donghang and Zhou, Mingzhu and Wei, Michael C and Kwan, Antonia and Zhao, Rong and Li, Chunze and Li, Chi-Chung and Turner, David C},
  title = {Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70211}
}
Kostenlos starten →